RESUMO
The T-lymphocyte proliferative response to phytohemoagglutinin (PHA) stimulation was the same in 11 anorexic women, 6 restricted (AN-R) and 5 bulimic (AN-B), and in 11 sex- and age-matched controls, in basal conditions and after acute administration of corticotropin-releasing hormone (CRH). Basal plasma levels of ACTH and cortisol were higher in patients than in controls, while beta-endorphin (beta-EP), growth hormone (GH) and prolactin (PRL) concentrations did not differ in the two groups. ACTH and beta-EP responses to CRH stimulation were blunted in patients, while those of cortisol did not differ in the two groups. ACTH, beta-EP and cortisol responses to the dexamethasone suppression test were impaired in 55% of the patients. Baseline T-lymphocyte concentrations of cholecystokinin-8 (CCK-8) and beta-EP were measured in another group of 56 anorexics, 33 restricted and 23 bulimic, and in 24 controls. CCK-8 values were significantly lower and beta-EP values significantly higher in patients than in controls.
Assuntos
Anorexia Nervosa/imunologia , Ativação Linfocitária/imunologia , Linfócitos T/imunologia , Adolescente , Hormônio Adrenocorticotrópico/sangue , Adulto , Bulimia/imunologia , Hormônio Liberador da Corticotropina , Feminino , Humanos , Hidrocortisona/sangue , Tolerância Imunológica/imunologia , Prolactina/sangue , Sincalida/sangue , beta-Endorfina/sangueRESUMO
Concentrations of cholecystokinin-8 (CCK-8) and beta-endorphin (beta-EP) in T-lymphocytes of 26 women with bulimia nervosa (BN) and in 26 age- and sex-matched healthy comparison subjects were measured. Ten patients were then treated with 300 mg/day of fluvoxamine, p.o., and five patients were treated with 300 mg/day of amineptine, p.o., for 4 months. Concentrations of the two peptides were measured again after 1, 2, and 4 months of therapy. Basal CCK-8 values were significantly lower in patients than in healthy subjects. During fluvoxamine therapy, CCK-8 values increased, reaching normal levels by month 4 of treatment. No such increase occurred during amineptine therapy. Baseline beta-EP values were normal in the bulimic patients but had declined by month 4 of fluvoxamine therapy.
Assuntos
Bulimia/sangue , Sincalida/sangue , Linfócitos T/metabolismo , beta-Endorfina/sangue , Adolescente , Adulto , Antidepressivos Tricíclicos/administração & dosagem , Bulimia/terapia , Terapia Cognitivo-Comportamental , Terapia Combinada , Dibenzocicloeptenos/administração & dosagem , Feminino , Fluvoxamina/administração & dosagem , Humanos , Pessoa de Meia-Idade , Inibidores Seletivos de Recaptação de Serotonina/administração & dosagem , Linfócitos T/efeitos dos fármacos , Resultado do TratamentoRESUMO
Twenty-two female patients with anorexia nervosa, restricted type, 14-35 years old, were treated with a 4-month course of combined cognitive-behavioral therapy, nutritional counselling and antidepressant drugs (nortriptyline for 7, fluoxetine for 15). Patients were monitored for body mass index (BMI), for eating disorder symptoms by the Eating Disorder Inventory (EDI) and the Bulimic Investigation Test (BITE) and for depression and anxiety by the Hamilton Rating Scales for Depression and for Anxiety (HRS-D and -A). The scores were determined before and after 1, 2 and 4 months of therapy. BMI, depression, anxiety and EDI scores improved significantly and equally in both groups during the 4 months of therapy, while BITE scores did not change.
Assuntos
Anorexia Nervosa/terapia , Terapia Comportamental , Terapia Cognitivo-Comportamental , Transtornos da Alimentação e da Ingestão de Alimentos/terapia , Fenômenos Fisiológicos da Nutrição , Adolescente , Adulto , Anorexia Nervosa/tratamento farmacológico , Anorexia Nervosa/psicologia , Antidepressivos de Segunda Geração/uso terapêutico , Antidepressivos Tricíclicos/uso terapêutico , Ansiedade/complicações , Ansiedade/tratamento farmacológico , Ansiedade/psicologia , Peso Corporal/fisiologia , Terapia Combinada , Depressão/complicações , Depressão/tratamento farmacológico , Depressão/psicologia , Transtornos da Alimentação e da Ingestão de Alimentos/tratamento farmacológico , Transtornos da Alimentação e da Ingestão de Alimentos/psicologia , Feminino , Fluoxetina/uso terapêutico , Humanos , Nortriptilina/uso terapêutico , Escalas de Graduação PsiquiátricaRESUMO
Thirteen women with anorexia nervosa, binge-eating/purging type (AN-BP), 17-43 years old, were treated with a 4-month course of combined cognitive-behavioral, nutritional and antidepressant therapy (7 with amineptine and 6 with fluoxetine). Patients were monitored before and after 1, 2 and 4 months of treatment for body mass index (BMI), for eating disorder symptoms by the Eating Disorder Inventory (EDI) and the Bulimic Investigation Test (BITE) and for depression and anxiety by the Hamilton Rating Scales for Depression and for Anxiety. BMI, EDI scores, depression and anxiety improved significantly and equally in the two groups during the 4 months of therapy, while BITE scores did not change.
Assuntos
Terapia Comportamental , Bulimia/terapia , Terapia Cognitivo-Comportamental , Transtornos da Alimentação e da Ingestão de Alimentos/terapia , Fenômenos Fisiológicos da Nutrição , Adolescente , Adulto , Antidepressivos de Segunda Geração/efeitos adversos , Antidepressivos de Segunda Geração/uso terapêutico , Antidepressivos Tricíclicos/efeitos adversos , Antidepressivos Tricíclicos/uso terapêutico , Ansiedade/complicações , Ansiedade/tratamento farmacológico , Ansiedade/psicologia , Bulimia/tratamento farmacológico , Bulimia/psicologia , Terapia Combinada , Depressão/complicações , Depressão/tratamento farmacológico , Depressão/psicologia , Dibenzocicloeptenos/efeitos adversos , Dibenzocicloeptenos/uso terapêutico , Transtornos da Alimentação e da Ingestão de Alimentos/tratamento farmacológico , Transtornos da Alimentação e da Ingestão de Alimentos/psicologia , Feminino , Fluoxetina/efeitos adversos , Fluoxetina/uso terapêutico , Humanos , Escalas de Graduação PsiquiátricaRESUMO
Fifteen women with bulimia nervosa were treated with a 4-month course of combined cognitive-behavioral, nutritional and antidepressant therapy (5 with amineptine and 10 with fluvoxamine). Patients were monitored before and after 1, 2 and 4 months of therapy for body mass index (BMI), for eating disorder symptoms by the Eating Disorder Inventory (EDI) and the Bulimic Investigation Test (BITE), and for depression and anxiety by the Hamilton Rating Scale for Depression and for Anxiety (HRS-D and -A). BITE symptoms and gravity improved significantly and equally in the two groups during the 4 months of therapy. Global EDI scores, depression and anxiety decreased but not significantly. BMI was normal before therapy and did not change during treatment.
